Loading people...
Alicia Yin is an Executive Director at 6 Dimensions Capital, a global healthcare venture capital firm managing over one billion dollars in assets, based in Palo Alto, California. In her current role, she focuses on venture investments and new company creation within the biotechnology and life sciences sectors. Prior to joining the firm in 2020, Yin worked as a biotech equity research analyst at HC Wainwright, where she covered more than forty small and mid cap biotechnology companies. She also gained corporate experience handling business development initiatives at Varian Medical Systems. Yin earned a PhD in Cancer Biology from Stanford Medical School, conducting research in the laboratory of Steve Artandi to identify novel transcription factors for telomerase in cancers. Her career combines deep scientific expertise with financial analysis to identify and support early stage therapeutic developers targeting challenging diseases.
Alicia Yin is a distinguished Managing Director at 6 Dimensions Capital, a globally recognized healthcare-focused venture capital firm. At 6 Dimensions Capital, which was formed from the strategic merger of Frontline BioVentures and WuXi Healthcare Ventures, Alicia plays a pivotal role in identifying and nurturing groundbreaking companies within the life sciences sector. Her investment focus is broad yet specialized, encompassing innovative therapeutics, advanced medical devices, diagnostics, and digital health solutions, often with a keen eye on opportunities that bridge the healthcare markets between China, the United States, and Europe.
Her extensive career background underscores her deep expertise in healthcare investment and strategy. Before her tenure at 6 Dimensions Capital, Alicia was a Partner at Frontline BioVentures, where she honed her skills in venture capital within the healthcare domain. Prior to that, she served as a Vice President at Fidelity Growth Partners Asia (FGPA), further solidifying her experience in healthcare-specific investments across Asia. Alicia also contributed her strategic insights as a consultant at McKinsey & Company, where she specialized in advising clients in the healthcare and private equity sectors, providing her with a foundational understanding of market dynamics and operational excellence.
Academically, Alicia Yin holds an MBA from Harvard Business School, a testament to her strong business acumen. She also possesses a Master of Science in Biomedical Engineering from Johns Hopkins University and a Bachelor of Science in Biomedical Engineering from Tsinghua University. This robust educational background in both business and biomedical science provides her with a unique perspective, enabling her to thoroughly evaluate the scientific merit and commercial potential of complex healthcare innovations.
While specific individual investments are often attributed to the firm, Alicia has been instrumental in shaping 6 Dimensions Capital's impressive portfolio. The firm is known for backing transformative companies such as Ascentage Pharma, Innovent Biologics, and Gracell Biotechnologies, among others. These investments reflect the firm's, and by extension Alicia's, commitment to supporting companies that are developing novel therapies and technologies to address significant unmet medical needs globally. Her work at 6 Dimensions Capital continues to drive innovation and growth within the global healthcare ecosystem, making her a key figure in the venture capital landscape.
Alicia Yin is a Managing Director at 6 Dimensions Capital, a leading healthcare-focused venture capital firm. She is known for her expertise in life science investments, particularly in pharmaceuticals, biotech, and medical devices.
Alicia Yin invests in innovative life science companies, focusing on areas such as novel therapeutics, advanced medical devices, diagnostics, and digital health. She often targets cross-border opportunities between China, the US, and Europe.
Alicia Yin works as a Managing Director at 6 Dimensions Capital, a prominent healthcare venture capital firm formed by the merger of Frontline BioVentures and WuXi Healthcare Ventures.
